Clinical Trials Browser

Interventional × Has results × binimetinib × Clear all

Lymphatic Metastasis, Melanoma

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Anatomic Stage IV Breast Cancer AJCC v8

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

Brain Neoplasms, Soft Tissue Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Advanced BRAF Mutant Cancers

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Pancreatic Neoplasms

Solid Tumors Harboring a BRAF V600 Mutation

Colorectal Neoplasms

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Colorectal Neoplasms

Low-grade Serous Ovarian Cancer

Brain Neoplasms, Melanoma

Pancreatic Neoplasms

Colorectal Neoplasms

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Noonan Syndrome 5, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Colorectal Neoplasms

Adenocarcinoma of Lung

Uveal Melanoma, Melanoma

Clinical Trials

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

COLUMBUS

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Study of MEK162 for Children With Low-Grade Gliomas

MEK162

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

EBRAIN-MEL

NF108-BINI

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

PALBOBIN

KEYNOTE-651

BRAF

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

QUAD01

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

LOGIC-2

ANCHOR-CRC

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

BEACON CRC

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

POLARIS

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

MErCuRIC1

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

SIGNATURE

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma